Compare EXG & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EXG | NRIX |
|---|---|---|
| Founded | N/A | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.5B |
| IPO Year | 2006 | 2020 |
| Metric | EXG | NRIX |
|---|---|---|
| Price | $9.89 | $26.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $30.50 |
| AVG Volume (30 Days) | 438.2K | ★ 1.0M |
| Earning Date | 01-01-0001 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $76,987,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $48.05 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 99.31 |
| 52 Week Low | $8.25 | $8.20 |
| 52 Week High | $10.16 | $28.23 |
| Indicator | EXG | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 52.06 | 64.21 |
| Support Level | $9.44 | $14.63 |
| Resistance Level | $10.16 | N/A |
| Average True Range (ATR) | 0.09 | 0.98 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 18.86 | 75.95 |
Eaton Vance Tax-Mgd Glbl Div Eq Inc is a diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary focus of the fund is capital appreciation. It invests in a diversified portfolio of domestic and foreign common stocks, emphasizing dividend-paying stocks. It writes call options on one or more U.S. and foreign indices for a portion of the value of its common stock portfolio to generate current cash flow from the options premium received. Its portfolio of investments consists of capital markets, banks, internet and direct marketing retail, biotechnology, media, oil, gas, consumable fuels, and other sectors.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.